Wake-up for Watson CEO in FTC Provigil deal probe: Frank Baldino still unwell
This article was originally published in Scrip
Executive Summary
Paul Bisaro, the President and CEO of Watson Pharmaceuticals, must comply with a US Federal Trade Commission subpoena to testify about a so-called "reverse-payment" patent settlement that Watson and other generics firms made with Cephalon in 2005 concerning Provigil (modafinil) that delayed generic competition, a district court judge has ruled in a 2 December opinion. Meanwhile Cephalon's Chairman and CEO, Frank Baldino, remains medically indisposed.